4-methoxy-5,6-dimethyl-pyrimidin-2-ylamine | 90221-19-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-methoxy-5,6-dimethyl-pyrimidin-2-ylamine
• 英文别名: 4-Methoxy-5,6-dimethyl-pyrimidin-2-ylamin；4-Methoxy-5,6-dimethylpyrimidin-2-amine
• CAS: 90221-19-5
• 化学式: C₇H₁₁N₃O
• 分子量: 153.184
• InChiKey: PFFANPXLFSULGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  61
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-methoxy-5,6-dimethyl-pyrimidin-2-ylamine 在 吡啶 、 sodium hydroxide 、 水 作用下， 生成 sulfanilic acid-(4-methoxy-5,6-dimethyl-pyrimidin-2-ylamide)
  参考文献：
  名称：

  Substituted Sulfanilamidopyrimidines¹

  摘要：

  DOI：

  10.1021/ja01204a044
• 作为产物：
  描述：

  2-甲基乙酰乙酸乙酯 在 甲醇 、 三氯氧磷 作用下， 生成 4-methoxy-5,6-dimethyl-pyrimidin-2-ylamine
  参考文献：
  名称：

  Substituted Sulfanilamidopyrimidines¹

  摘要：

  DOI：

  10.1021/ja01204a044

文献信息

• [EN] BENZOXAZEPINES AS INHIBITORS OF MTOR AND METHODS OF THEIR USE AND MANUFACTURE<br/>[FR] BENZOXAZÉPINES EN TANT QU'INHIBITEURS DE MTOR ET PROCÉDÉS DE LEURS UTILISATION ET FABRICATION
  申请人：EXELIXIS INC

  公开号：WO2012071511A1

  公开（公告）日：2012-05-31

  The invention is directed to inhibitors of mTOR and pharmaceutically acceptable salts or solvates thereof, as well as methods of using them. The inhibitors are generally of structural Formula (I) wherein the variables are as defined herein.

  该发明涉及mTOR的抑制剂及其药用盐或溶剂化合物，以及使用它们的方法。这些抑制剂通常具有结构式（I），其中变量如本文所定义。
• BENZOXAZEPINES ASN INHIBITORS OF P13K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE
  申请人：Rice Kenneth D.

  公开号：US20140073628A1

  公开（公告）日：2014-03-13

  The invention is directed to inhibitors of mTOR and pharmaceutically acceptable salts or solvates thereof, as well as methods of using them. The inhibitors are generally of structural formula I and pharmaceutically acceptable salts thereof, wherein the variables are as defined herein.

  本发明涉及mTOR的抑制剂及其药学上可接受的盐或溶剂，以及使用它们的方法。抑制剂通常具有结构式I及其药学上可接受的盐，其中变量如本文所定义。
• BENZOXAZEPINES AS INHIBITORS OF mTOR AND METHODS OF THEIR USE AND MANUFACTURE
  申请人：Rice Kenneth

  公开号：US20140018347A1

  公开（公告）日：2014-01-16

  The invention is directed to inhibitors of mTOR and pharmaceutically acceptable salts or solvates thereof, as well as methods of using them. The inhibitors are generally of structural Formula (I) wherein the variables are as defined herein.

  本发明涉及mTOR的抑制剂及其药学上可接受的盐或溶剂，以及使用它们的方法。抑制剂通常具有结构式（I），其中变量如本文所定义。
• Backer; Grevenstuk, Recueil des Travaux Chimiques des Pays-Bas, 1945, vol. 64, p. 115,120
  作者：Backer、Grevenstuk

  DOI：——

  日期：——
• IN VIVO PRODUCTION OF PROTEINS
  申请人：ModernaTX, Inc.

  公开号：US20210077634A1

  公开（公告）日：2021-03-18

  The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.